Triple
T16185341
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | Office of Pharmaceutical Quality |
E392785
|
entity |
| Predicate | worksWith |
P398
|
FINISHED |
| Object | Office of New Drugs |
E85252
|
NE FINISHED |
How this triple was built (2 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Office of New Drugs | Statement: [Office of Pharmaceutical Quality, worksWith, Office of New Drugs]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Office of New Drugs Context triple: [Office of Pharmaceutical Quality, worksWith, Office of New Drugs]
-
A.
Center for Drug Evaluation and Research
chosen
The Center for Drug Evaluation and Research is the U.S. FDA division responsible for overseeing the safety, effectiveness, and quality of prescription and over-the-counter drugs.
-
B.
Center for Biologics Evaluation and Research
The Center for Biologics Evaluation and Research is the U.S. regulatory body responsible for overseeing the safety, efficacy, and quality of biological products such as vaccines, blood products, and gene therapies.
-
C.
Office of Generic Drugs
The Office of Generic Drugs is a division of the U.S. Food and Drug Administration responsible for reviewing and approving generic medications to ensure they are safe, effective, and therapeutically equivalent to brand-name drugs.
-
D.
Office of Regulatory Affairs
The Office of Regulatory Affairs is the U.S. FDA’s primary field organization responsible for inspecting regulated products and manufacturers, enforcing compliance, and overseeing import operations to protect public health.
-
E.
Food and Drug Administration
The Food and Drug Administration is a U.S. federal agency responsible for protecting public health by regulating food, drugs, medical devices, and other consumer products.
- F. None of above.
- G. Unsure - the case is ambiguous/there is not enough information to decide.
Provenance (3 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69d87f1e49ac8190a311b54d32990576 |
completed | April 10, 2026, 4:39 a.m. |
| NER | Named-entity recognition | batch_69e22060dcf88190b7c662946a5f0191 |
completed | April 17, 2026, 11:58 a.m. |
| NED1 | Entity disambiguation (via context triple) | batch_6a001f860ecc8190be904fa793968d89 |
completed | May 10, 2026, 6:02 a.m. |
Created at: April 10, 2026, 5:02 a.m.